Phase 2 trial to evaluate immunomodulating diet enriched with whey peptide by perioperative administration in pancreatoduodenectomy for hepato-biliary-pancreatic malignancy

Phase 2 trial to evaluate immunomodulating diet enriched with whey peptide by perioperative administration in pancreatoduodenectomy for hepato-biliary-pancreatic malignancy - NEW-PASSO

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012231

Enrollment

100

Registered

2013-12-01

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreas cancer,bile duct cancer, ampullary cancer

Interventions

Intervention:The volume of administrated immunomodulating diet is 600ml/day. Intervention:The volume of administrated standard diet is 600ml/day.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with pancreas,bile duct and ampullary cancer who will undergo pancreatoduodenectomy

Exclusion criteria

Exclusion criteria: Patients who cannot tolerate enteral nutrition and who have severe heart, respiratory, renal,liver dysfunction and severe malnutrition are excluded.

Design outcomes

Primary

Measure	Time frame
incidence of infectious/non-infectious complication	—

Secondary

Measure	Time frame
length of post-operative hospital stay mortality rate serum cytokine level etc.	—

Countries

Japan

Contacts

Public ContactTomoyuki Moriya

National Defense Medical College Hospital Department of Surgery

tmoriya@ndmc.ac.jp04-2995-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026